Nonclinical Safety Assessment

Oct 14
A map of the nonclinical safety package

A map of the nonclinical safety package: what ICH M3(R2) requires before first-in-human dosing

Before a new medicine is given to a human for the first time, regulators expect a defined set of nonclinical
4 min read
Oct 14
More than sixty years later, they shape how drug developers design safety programmes, and they are moving from an ethical principle to a regulatory reality.

The 3Rs in practice: where in vitro models like macrophage assays fit in early safety assessment

The 3Rs, Replacement, Reduction and Refinement, were proposed by William Russell and Rex Burch in 1959 (Russell & Burch, 1959)
4 min read